

MOL # 116319

T-cell protein tyrosine phosphatase (TCPTP) is irreversibly inhibited by etoposide-quinone, a reactive metabolite of the chemotherapy drug etoposide

Qing NIAN, Jérémy BERTHELET, Wenchao ZHANG, Linh-Chi BUI, Rongxing LIU, Ximing XU, Romain DUVAL, Saravanan GANESAN, Thibaut LEGER, Christine CHOMIENNE, Florent BUSI, Fabien GUIDEZ, Jean-Marie DUPRET and Fernando RODRIGUES LIMA

Université de Paris, BFA, UMR 8251, CNRS, F-75013, Paris, France (QN, JB,WZ, LCB,RL, FB, JMD, FRL); Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China (XX); Université de Paris, BIGR, UMRS 1134, INSERM, F-75015, Paris, France (RD); Université de Paris, Institut de Recherche Saint-Louis, UMRS 1131, INSERM, F-75010, Paris, France (SG, CC, FG); Université de Paris, IJM, UMR 7592, CNRS, F-75013, Paris, France (TL); Service de Biologie Cellulaire, Assistance Publique des Hôpitaux de Paris, Hôpital Saint Louis, F-75010, Paris, France (CC)

MOL # 116319

Running title: Etoposide quinone impairs the phosphatase activity of TCPTP

Corresponding author: Fernando RODRIGUES LIMA, Université de Paris, BFA, UMR 8251, CNRS, F-75013, Paris, France; email: fernando.rodrigues-lima@univ-paris-diderot.fr

Text pages: 31

Tables : 0

Figures : 7

References : 44

Abstract : 200 words

Introduction : 661

Discussion : 910

Abbreviations: DTT: dithiothreitol; ETOP: etoposide; EQ: etoposide ortho-quinone; IAF: fluorescein 5-iodoacetamide; MPO: myeloperoxidase; NBT: nitroblue tetrazolium; pNPP: p-nitrophenyl phosphate; PTPN2: Tyrosine-protein phosphatase non-receptor type 2; TCPTP: T-cell protein tyrosine phosphatase.

MOL # 116319

ABSTRACT

Etoposide is a widely prescribed anticancer drug that is, however, associated with an increased risk of secondary leukaemia. Although the molecular basis underlying the development of these leukaemias remains poorly understood, increasing evidence implicates the interaction of etoposide metabolites (*i.e.* etoposide quinone, EQ) with topoisomerase II enzymes. However, effects of etoposide quinone on other cellular targets could also be at play. We investigated whether TCPTP, a protein tyrosine phosphatase that plays a key role in normal and malignant haematopoiesis through regulation of JAK/STAT signalling could be a target of EQ.

We report here that EQ is an irreversible inhibitor of TCPTP phosphatase ($IC_{50} = \sim 7 \mu\text{M}$, second-order rate inhibition constant of $\sim 810 \text{ M}^{-1} \cdot \text{min}^{-1}$). No inhibition was observed with the parent drug. The inhibition by EQ was found to be due to the formation of a covalent adduct at the catalytic cysteine residue in the active site of TCPTP. Exposure of human hematopoietic cells (HL-60 and Jurkat) to EQ led to inhibition of endogenous TCPTP and concomitant increase in STAT1 tyrosine phosphorylation. Our results suggest that in addition to alteration of topoisomerase II functions, EQ could also contribute to ETOP-dependent leukaemogenesis through impairment of key hematopoietic signalling enzymes such as TCPTP.

MOL # 116319

INTRODUCTION

Protein tyrosine phosphatases (PTPs) are important regulators of the activity of numerous signalling pathways involved in major cellular processes such as cell growth, proliferation and differentiation (Tonks, 2006; Tiganis et al., 2007; Pike et al., 2016). T-cell protein tyrosine phosphatase (TCPTP) is a cytosolic tyrosine phosphatase which is ubiquitously expressed. However, the highest levels of expression of TCPTP are found in haematopoietic cells where this enzyme modulates growth factor and cytokine signalling pathways, thus contributing to immune and hematopoietic cell homeostasis (Wiede et al., 2012; Pike et al., 2016). In particular, TCPTP negatively regulates JAK/STAT signalling through the dephosphorylation of different tyrosine phosphorylated JAK/STAT proteins such as STAT1 or JAK1 (ten Hoeve et al., 2002; Dorritie et al., 2014; Pike et al., 2016). In addition to STAT1, TCPTP also dephosphorylates STAT3 and STAT5 and negatively regulates their activation (Pike et al., 2016). The JAK/STAT pathway plays a crucial role in haematopoiesis and aberrant activation of STAT signalling is involved in leukaemogenesis (Dorritie et al., 2014; Pike et al., 2016). Interestingly, deletions or inactivating mutations of TCPTP were identified in T-cell leukaemia and non-Hodgkin's lymphoma and associated with elevated STAT signalling and changes in gene expression (Kleppe et al., 2010; Kleppe et al., 2011a; Kleppe et al., 2011b; Pike et al., 2016). In addition, it has been reported that TCPTP is overexpressed in MYC-driven mouse B cell lymphoma (Young et al. 2009). The importance of TCPTP in haematopoiesis is further supported by knockout mouse models (PTPN2^{-/-}), where the absence of TCPTP induces severe hematopoietic defects (affecting lymphoid, myeloid and erythroid lineages) and progressive systemic inflammation leading to death (You-Ten et al., 1997; Bourdeau et al., 2007; Heinonen et al., 2009; Wiede et al., 2012). These studies highlight the important role of TCPTP in normal and malignant haematopoiesis.

MOL # 116319

Etoposide (ETOP) is a widely used anticancer drug to treat a variety of human malignancies (Hande, 1998; Baldwin et al., 2005). The mechanisms of action proposed for its antitumor activity are based mainly on its interaction with topoisomerases II (Baldwin et al., 2005; Deweese et al., 2009). ETOP is indeed known to affect the catalytic cycle of these enzymes and to stabilize topoisomerase II-bound DNA strand breaks which have the potential to activate cell death pathways (Jacob et al., 2011). Despite the wide clinical use of ETOP, this chemotherapeutic drug is known to induce treatment-related leukaemias (Baldwin and Osheroff, 2005; Pendleton et al., 2014). In humans, ETOP can be oxidized by cytochrome P450 (CYP3A4) and myeloperoxidases into etoposide quinone (EQ) which was found to have an effect on topoisomerase II enzymes several times stronger than that of the parent drug (Zhuo et al., 2004; Fan et al., 2006; Jacob et al., 2011; Vlasova et al., 2011). Although the molecular basis for ETOP-induced leukaemogenesis is not well understood, evidence increasingly indicates that EQ is a critical contributor to the development of ETOP-related secondary leukaemia, in particular through alteration of topoisomerase II-functions (Gantchev and Hunting, 1998; Kagan et al., 1999; Fan et al., 2006; Vlasova et al., 2011; Smith et al., 2014; Gibson et al., 2016). However, interactions of ETOP reactive metabolites with other cellular proteins and macromolecules may also contribute to ETOP-dependent leukaemogenesis (Fan et al., 2006; Rojas et al., 2009).

We show here that EQ is an irreversible inhibitor of TCPTP phosphatase activity. Kinetic and molecular analyses using purified human TCPTP indicated that the irreversible inhibition of the enzyme by EQ is due to the formation of a covalent adduct with its catalytic cysteine. Accordingly, exposure of cultured hematopoietic cells to EQ leads to the irreversible inhibition of the endogenous TCPTP with a concomitant increase in cellular STAT1 phosphorylation. Interestingly, it is well known that dysregulation of the JAK/STAT

MOL # 116319

signalling pathway is involved in leukaemogenic processes (Benekli et al., 2009; Dorritie et al., 2014). Altogether, our data suggest that in addition to the disruption of topoisomerase II functions, EQ may also contribute to ETOP-related leukaemia through alteration of important hematopoietic signaling enzymes such as TCPTP.

MOL # 116319

METHODS

Chemicals and cells

Etoposide (ETOP) and etoposide quinone (EQ) were obtained from Toronto Research Chemicals (North York, Canada). Hydrogen peroxide, *N*-ethylmaleimide (NEM), fluorescein 5-iodoacetamide (5-IAF), myeloperoxidase (MPO), *p*-nitrophenyl phosphate (pNPP), sodium orthovanadate, nitroblue tetrazolium (NBT), dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (France). ETOP and EQ were diluted in DMSO at a stock concentration of 100 mM. HL60 (human acute promyelocytic leukaemia) and Jurkat (human acute T cell leukaemia) cells were from Sigma-Aldrich (France).

Expression and purification of recombinant human TCPTP enzyme

Human TCPTP enzyme was expressed and purified as previously described (Duval et al., 2015), using BL21(DE3) *Escherichia coli*, transformed with a pET28a plasmid containing the cDNA of human PTNP2 (TC45 variant). The purified enzyme was reduced by incubation with 10 mM DTT for 10 minutes in ice before buffer-exchange with PD-10 column (GE Healthcare, France) into 25 mM Tris-HCl, 150 mM NaCl, pH 7.5 (reaction buffer). The protein concentration was determined by the Bradford reagent (Bio-Rad, France), and purity was assessed by SDS-PAGE and Coomassie staining. Purified recombinant human TCTPT (1 mg/ml) was stored at -80°C until use.

Determination of TCPTP activity using *p*-nitrophenyl phosphate (pNPP assay)

The phosphatase activity was measured using *p*-nitrophenyl phosphate (pNPP) as substrate as described previously (Montalibet et al., 2005). Typically, samples containing TCPTP were diluted 10 times with 100 mM sodium acetate buffer (pH 6, 1 mM DTT) containing 5 mM

MOL # 116319

pNPP. The formation of the product (*p*-nitrophenol) was tracked by continuous measurement of the absorbance at 405 nm at 37 °C using a thermostatic microplate reader (BioTek, France) in a total volume of 250 µl. The final concentration of TCPTP during the assay was 100 nM.

Determination of TCPTP activity using a tyrosine-phosphorylated STAT1 peptide (FAM-pSTAT1)

The tyrosine phosphatase activity of TCPTP was measured by reverse phase fast liquid chromatography (RP-UFLC) using a fluorescein (FAM)-conjugated peptide derived from the sequence of human STAT1 (₆₉₇KGTGYIKTE₇₀₅ where the Y701 is phosphorylated) as described previously (Duval et al., 2015). Briefly, samples containing TCPTP were diluted 100-fold with acetate buffer. Aliquots (100 µl) were incubated for 30 min at 37 °C in presence of 50 µM FAM-pSTAT1 peptide (final concentration of TCPTP was 10 nM). The reaction was stopped with 100 µl of 15% HClO₄ (v/v) prior to analysis by RP-UFLC using a Shim-pack XR ODS column (Shimadzu, France) connected to a Prominence Shimadzu UFLC system.

Effects of etoposide and etoposide quinone on TCPTP activity

Recombinant TCPTP (1 µM) was incubated with ETOP or different concentrations of EQ in 100 mM sodium acetate, pH 6 for 30 minutes at 37 °C (total volume of 50 µl). Samples were diluted 10 times then assayed for residual TCPTP activity using pNPP. To obtain the IC₅₀ value, the dose-response curves were fitted with the Hill equation, $TCPTP_{activity} = 100 / (1 + 10^{((\text{Log}IC_{50} - [EQ]) * \text{Hillslope}))}$, where IC₅₀ is the half maximal inhibitory concentration of EQ. The effects of ETOP and EQ on the TCPTP tyrosine phosphatase activity

MOL # 116319

were also assessed by a RP-UFLC approach using a tyrosine phosphorylated STAT1 peptide (see above).

Effects of reducing agents and buffer exchange on TCPTP inhibited by EQ

TCPTP (1 μM) was first incubated with EQ (40 μM) or ETOP (100 μM) in 100 mM sodium acetate, pH 6 for 30 min at 37°C (total volume of 50 μl). Samples were either incubated with 1 or 10 mM DTT (10 min at room temperature) or buffer exchanged (PD Spin Trap G-25, GE Healthcare, France) to 100 mM sodium acetate, pH 6, prior to measurement of residual TCPTP activity using pNPP.

Fluorescein-conjugated iodoacetamide labelling, nitroblue tetrazolium staining and detection of oxidized TCPTP catalytic cysteine

TCPTP (1 μM) was first incubated with ETOP (100 μM) or EQ (40 μM) in 100 mM sodium acetate pH 6 at 37°C for 30 min followed by the addition of 20 μM 5-IAF (total volume of 50 μl) and further incubation at 37 °C for 10 min (in the dark). Samples were separated by SDS-PAGE and transferred onto nitrocellulose membranes. 5-IAF covalent labelling of TCPTP cysteine residues was detected by western blot using anti-fluorescein antibodies (Sigma-Aldrich, France, ref: # 11426346910). Membranes were stripped and further probed with anti-TCPTP antibody (Sigma-Aldrich, France, ref: # SAB4200249).

The formation of covalent adducts of EQ on TCPTP was detected by nitroblue tetrazolium (NBT) redox cycling staining as reported previously (Paz et al., 1991) . Briefly, TCPTP (1 μM) was incubated with ETOP (100 μM) or EQ (40 μM) in 100 mM sodium acetate pH 6 at 37°C for 30 min (total volume 50 μl). Samples were separated by SDS-PAGE and transferred onto nitrocellulose membranes. EQ-bound TCPTP on the membranes was stained by

MOL # 116319

incubation with 0.6 mg/ml NBT in 2 M potassium glycinate pH 10 for 30-45 min in the dark at room temperature. Next, membranes were washed thoroughly with PBS and further probed with anti-TCPTP antibody (Sigma-Aldrich, France, ref: # 11426346910).

For the detection of oxidized TCPTP catalytic cysteine, TCPTP (1 μ M) was treated with ETOP (100 μ M), EQ (40 μ M) or H₂O₂ (100 μ M) in a total volume of 50 μ l. Aliquots were then separated by SDS-PAGE and analysed by western blot with a specific anti-oxidized PTP active site antibody (R&D system, USA, ref:# MAB 2844) as described previously (Duval et al., 2015).

Effects of myeloperoxidase (MPO)-dependent bioactivation of ETOP into EQ

Myeloperoxidase was used to bioactivate ETOP into EQ as described previously (Kagan et al., 1999; Fan et al., 2006; Vlasova et al., 2011). To this end, MPO (5 units) was incubated with ETOP (100 μ M) and H₂O₂ (100 μ M) in 100 mM sodium acetate, pH 6.5 for 30 min at room temperature (in a total volume of 1 ml). Heat-inactivated MPO (boiled for 30 min) was used as a negative control. Catalase (300 Units/ml final concentration) was added to remove excess H₂O₂. Finally, reaction mix (48 μ l) was added to recombinant TCPTP (1 μ M final concentration) in 100 mM sodium acetate, pH 6 and incubated for 30 min at 37°C (total volume of 50 μ l). After incubation, and a ten-times dilution, the residual activity of TCPTP was measured using the pNPP assay. IAF and NBT labelling and detection of oxidized TCPTP catalytic cysteine were also carried out on TCPTP treated with MPO as described above.

Kinetics of TCPTP inhibition by EQ

The kinetic data were analysed as reported in Copeland (2005) for irreversible inhibitors. The kinetic data were fitted and plotted using Qtiplot software (<http://www.qtiplot.com/>).

MOL # 116319

Briefly, TCPTP (3 μM) was incubated with different concentrations of EQ (pseudo first-order conditions) in 100 mM sodium acetate pH 6 at 37°C. At different time point, aliquots were removed and assayed for residual TCPTP activity using pNPP assay. The rate of inhibition of TCPTP by EQ can be represented as: $\text{Ln} [\% \text{ residual activity}] = k_{\text{obs}} \times t$ (where t is time and k_{obs} is the apparent first-order inhibition rate constant). The apparent first order inhibition rate constants ($k_{\text{obs}} = k_{\text{inact}} \times [\text{EQ}]$) can be calculated for each EQ concentration from the slope of the natural log (Ln) of percent residual activity plotted against time. The second-order rate constant (k_{inact}) was determined from the slope of k_{obs} plotted against EQ concentrations.

Effects of EQ on TCPTP in the presence of the competitive PTP inhibitor orthovanadate (Na_3VO_4)

TCPTP (1 μM) was incubated with 1 mM orthovanadate in the presence of absence of EQ (40 μM) in 100 mM sodium acetate pH 6 at 37 °C for 30 min. Samples were diluted ten times in 100 mM sodium acetate pH 6 containing 1 mM EDTA and residual TCPTP activity measured using pNPP assay.

Molecular docking

TCPTP protein structure data was obtained from RCSB PDB database (PDB_ID 1L8K). The protein structure was prepared using the Prepwizard module in the Schrodinger suite (Schrödinger LLC, 2019, <https://www.schrodinger.com>). Briefly, missing side chains or loops were completed. The pKa values of residues were predicted and hydrogens were added at pH7. Water molecules were removed. Finally, the structure was optimized by a restrained energy minimization with OPLS3 force field. The ligand (EQ) was constructed by Maestro module and was also refined by OPLS3 force field. Covalent-docking was carried out with the

MOL # 116319

catalytic residue Cys 216 selected as the docking centre. Grid box size was set to 20x20x20 Å³. Michael addition reaction type was selected for the covalent docking. The final conformation was selected, and images were prepared with VMD program (Humphrey et al., 1996).

Mass spectrometry analysis

TCPTP (1 µM) was incubated with 100 µM EQ for 30 min at 37°C in 100 mM sodium acetate pH 6. After reduction with DTT (10 mM), the samples were diluted 10 times in sodium acetate buffer and unmodified thiol moieties of cysteines were blocked by addition of 10 mM NEM for 10 min. Samples were then incubated overnight at 37 °C with trypsin (Promega, France) at 12.5 ng/µl in 25 mM ammonium bicarbonate pH 8.0. The supernatant containing peptides was acidified with formic acid (FA), desalted on C18 tips (Pierce C18 tips, Thermo Scientific), and eluted in 10 µl 70% ACN, 0.1% FA. Desalted samples were evaporated using a SpeedVac then taken up in 10 µl of buffer A (buffer A: water, 0.1% FA) and 5µl were injected on a nanoLC HPLC system (Thermo Scientific, France) coupled to a hybrid quadrupole-Orbitrap mass spectrometer (Thermo Scientific, France). Peptides were loaded on a reverse phase C18 µ-precolum (C18 PepMap100, 5µm, 100A, 300 µm i.d.x5 mm) and separated on a C18 column (EASY-spray C18 column, 75 µm i.d.x50 cm) at a constant flow rate of 300 nl/min, with a 120 min gradient of 2 to 40% buffer B (buffer B: 20% water, 80% ACN, 0.1% FA). MS analyses were performed by the Orbitrap cell with a resolution of 120.000 (at *m/z* 200). MS/MS fragments were obtained by HCD activation (collisional energy of 28%) and acquired in the ion trap in top-speed mode with a total cycle of 3 seconds. The database search was performed against the Swissprot database (02/2017) and the *Homo sapiens* taxonomy with Mascot v2.5.1 software with the following

MOL # 116319

parameters: tryptic peptides only with up to 2 missed cleavages, variable modifications: cysteine EQ and methionine oxidation. MS and MS/MS error tolerances were set respectively to 7 ppm and 0.5 Da. Peptide identifications were validated using a 1% False Discovery Rate (FDR) threshold obtained by Proteome Discoverer (version 2.2, Thermo Scientific) and the percolator algorithm. The candidate sequences modified by EQ were manually inspected for *de novo* sequencing.

Cell culture, TCPTP immunoprecipitation and STAT1 phosphorylation kinetics

HL60 and Jurkat cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated foetal bovine serum and 1 mM L-glutamine in T-75 flasks. Cells (60 ml at 2×10^6 cells/ml) were washed with PBS prior to exposure to 50 μ M EQ (or DMSO) for 30 min at 37°C (5% CO₂) in RPMI 1640 medium.

For immunoprecipitation of endogenous TCPTP, treated cells were washed with PBS and resuspended in lysis buffer (PBS, 1% Triton X-100, 1 mM sodium orthovanadate, phosphatase cocktail inhibitor 2 and protease inhibitors cocktail (Sigma-Aldrich, France) for 20 min. Cell lysates were centrifuged at 15000 x g for 10 min at 4°C and supernatants (whole cell extracts) were taken. TCPTP was immunoprecipitated by incubating 1 mg of whole cell extracts with 1 μ g of polyclonal TCPTP antibody (Sigma-Aldrich, France, [ref:# SAB4200249](#)) overnight at 4°C. Samples were then rocked for one hour at 4° C in presence of 30 μ l of protein A–Agarose (Santa Cruz, Germany). The immunobeads were harvested by centrifugation, washed 3 times with lysis buffer and split into two portions. One part of the beads was incubated with 50 μ M of FAM-pSTAT1 peptide in order to measure residual immunoprecipitated-TCPTP activity by RP-UFLC as described above. The second part of immunobeads was incubated with non-reducing Laemmli sample buffer. Eluates were

MOL # 116319

separated by SDS-PAGE and analysed by western blot using with an anti-TCPTP antibody (R&D System, USA, ref: # MAB 1930).

For the STAT1 phosphorylation kinetic analysis, cells treated with EQ or DMSO were washed with fresh medium and incubated for 20 min in medium supplemented with 10 ng/ml of human IFN γ . Cells were then washed in fresh medium and aliquots (2×10^6 cells) were removed at different time points, washed with PBS and lysed. STAT1 activation was then assayed in lysates by western blot using anti-phospho-STAT1 (phosphorylated Tyrosine 701, Cell Signaling, France, ref: #9176). Membranes were re-probed sequentially with anti-STAT1 (Cell Signaling, France, ref: #9167), anti-TCPTP (Sigma-Aldrich, France, ref: #SAB4200249) and anti- β actin (Cell Signaling, France, ref: #3700) antibodies. Quantification of STAT1 phosphorylation in western blots was carried out using ImageJ software (Schneider et al., 2012).

Statistical analysis

The study was designed in such a manner that three independent replicates are conducted for each experiment prior to statistical analysis. All data are expressed as the mean \pm standard deviation (SD). All statistical analyses were then carried out using Prism 5.03 (GraphPad Software, La Jolla, CA) with a P-value < 0.05 threshold to consider differences as statistically significant. For experiments where multiple groups were compared to control, a one-way analysis of variance (ANOVA) was used. If statistical significance was reached, data were further analyzed with Dunnett's posthoc test. For experiments between two groups, a two-tailed Student's t test was used. No experiment was removed from the final analysis. For qPCR experiments (supplementary figure 3), 6 experimental points were used in data

MOL # 116319

analysis, which consisted in a Student's t test to compare the effect of EQ vs control in cells induced with interferon gamma.

MOL # 116319

RESULTS

Effect of etoposide quinone on activity of TCPTP

The effects of ETOP and EQ were assessed on the activity of recombinant human TCPTP expressed and purified from bacteria. As a first experiment, TCPTP was incubated in the presence of 100 μM ETOP or increasing concentrations of EQ prior to the measurement of the residual enzyme activity with the chromogenic pNPP phosphatase substrate. As shown in Figure 1A, EQ inhibits the hydrolysis of this substrate in a dose-dependent manner with half-maximal inhibitory concentration (IC_{50}) values of 7.3 μM (supplementary Figure 1). Conversely, 100 μM ETOP did not display any inhibitory effect, therefore suggesting that inhibition of TCPTP activity could occur with EQ but not with the parent drug. These results were further validated with a UFLC-based enzyme assay using a more specific TCPTP substrate consisting of a phospho-STAT1 peptide derived from the sequence of human STAT1 ($_{697}\text{KGTGYIKTE}_{705}$ where the Y701 is phosphorylated) as described in (Duval et al., 2015). UFLC quantification of the dephosphorylated STAT1 confirms that EQ but not ETOP inhibits TCPTP phosphatase activity (Figure 1B).

Etoposide quinone covalently reacts with TCPTP cysteine residues

As EQ but not ETOP inhibits TCPTP activity, we next hypothesized that this inhibition could result from the general chemical reactivity properties of quinone chemicals and notably the possibility that they react covalently with proteins (Bolton et al., 2017; Bolton et al., 2018). Nitroblue tetrazolium (NBT) can be used to stain proteins covalently modified by quinones to form quinone-proteins. As shown in Figure 2A, NBT reaction generated only a signal when TCPTP was treated with EQ, confirming the presence of covalent quinone adducts on TCPTP.

MOL # 116319

Knowing that protein cysteinyl residues are common nucleophilic targets of quinone electrophiles, we therefore strived to show whether TCPTP cysteinyl residues could be modified after exposure to EQ. TCPTP was treated with EQ and then incubated with fluorescein-conjugated iodoacetamide (IAF), a specific cysteinyl thiol reagent. Our results (Figure 2B) show that EQ decreased IAF labelling of TCPTP, therefore indicating that EQ reacts with cysteine residues of TCPTP.

Quinones chemicals can also display redox cycling properties that leads to generation of reactive oxygen species (ROS). In addition, it is known that TCPTP can be inhibited by reactive oxygen species through the oxidation of its catalytic cysteine residue (Ostman et al., 2011). We therefore evaluated whether EQ could oxidize the catalytic cysteine residue of TCPTP using an antibody specifically directed against oxidized catalytic cysteine residue of protein tyrosine phosphatases (Duval et al., 2015). Figure 2C shows that EQ treatment does not lead to TCPTP active site cysteine oxidation, and, in addition, that the basal oxidation of catalytic cysteine achieved during experiment and observed in control and ETOP treatment is decreased with EQ. This is agreement with the formation of an EQ adduct on the catalytic cysteine of the enzyme. Therefore, these data altogether suggest a loss of TCPTP activity due to EQ adduction of the catalytic cysteine.

When clinically administered to patients, ETOP is biochemically metabolized to EQ by different enzymes notably myeloperoxidase which is highly expressed in bone marrow hematopoietic cells (Fan et al., 2006; Atwal et al., 2017). To test if EQ generated from peroxidase/H₂O₂-dependent bioactivation of ETOP would yield similar TCPTP inhibition, we used an *in vitro* peroxidase activation system that mimics the bioactivation of ETOP into EQ in hematopoietic cells described previously (Kagan et al., 1999; Vlasova et al., 2011). As shown in Supplementary Figure 2A, in presence of a functional peroxidase/H₂O₂ enzymatic

MOL # 116319

system, ETOP is capable of inhibiting TCPTP activity with concomitant quinone-adduction (NBT labelling) and loss of IAF cysteine labelling of TCPTP protein (Supplementary Figure 2B and C). Conversely, when inactive peroxidase is used, no inhibition of TCPTP and quinone adduction on cysteine residues is observed (supplementary Figure 2). This confirms that EQ but not the parent drug can inhibit TCPTP activity through covalent adduction, a result which is consistent with the electrophilic nature of the quinone moiety of EQ which enables Michael addition with thiol groups (Fan et al., 2006; Bolton et al., 2018).

Identification of the catalytic cysteine residue of TCPTP as a target of EQ

Orthovanadate, a transition state analogue generally used as a competitive protein phosphotyrosine phosphatase inhibitor, was used to evaluate whether EQ inhibition involves reactions at the active site of the enzyme as described previously (Seiner et al., 2007). Figure 3A shows that vanadate confers protection to TCPTP as the inhibition of the enzyme is significantly slowed by the competitive inhibitor thereby providing evidence that the reaction is active-site directed. Computational analysis using covalent docking approaches further indicated that the catalytic cysteine of TCPTP (Cysteine 216) can form an adduct in the active site through the formation of a covalent bond between the sulphur atom and the carbon 6' of the quinone moiety (Figure 3B).

In order to ascertain that the catalytic cysteine residue of TCPTP can be covalently adducted by EQ, we analysed recombinant protein treated with EQ using LC-MS-MS. As shown in Figure 3C, the $[M+3H]^{3+}$ molecular ion of the tryptic peptide harbouring the catalytic cysteine displays a 190.9 m/z increase after treatment with EQ, corresponding to the mass of the EQ adduct. This mass of EQ adduct is also confirmed in the $a16^{2+}$, $y17^{2+}$ and $y20^{3+}$ ions of the fragmented peptide. It is well-known that tyrosine phosphatases are readily inhibited

MOL # 116319

by chemicals able to modify their catalytic cysteine (Seiner et al., 2007; Ostman, Frijhoff et al., 2011). Altogether these experiments indicate that EQ impairs TCPTP activity through the covalent adduction of its catalytic cysteine.

Characterization of reversibility and kinetics of TCPTP inhibition by EQ

TCPTP inhibition by EQ was further evaluated for reversibility. To this end, TCPTP enzyme was inhibited by EQ and subsequently subjected to a buffer exchange experiment before measuring its residual activity. Consistent with the data described above, buffer exchange could not restore TCPTP activity (Figure 4A). Depending on the chemical structure of the quinones, reversibility of cysteine adducts through reduction has already been described (Bolton et al., 2017; Bolton et al., 2018). We therefore examined the effect of two concentrations of the reducing agent DTT on the reversion of TCPTP inhibition by EQ. As shown in Figure 4B, even at a 10 mM concentration, DTT was not successful at restoring the activity of EQ-inhibited TCPTP, thereby confirming the stable and covalent nature of the reaction between EQ and the catalytic cysteine of TCPTP. These observations are consistent with previously published data on the inhibition of topoisomerases II by EQ (Jacob et al., 2011; Smith et al., 2014 ; Gibson et al., 2016).

Finally, the kinetics of TCPTP inhibition by EQ were studied under pseudo-first order conditions which allowed observation of time- and dose-dependent inhibition (Figure 5A) and permitted the determination of the second order inhibition kinetic constant $k_{\text{inact}} = \sim 810 \pm 73 \text{ M}^{-1} \cdot \text{min}^{-1}$ derived from the slope of the graph with pseudo-first order kinetic constants plotted against EQ concentration (Figure 5B). This kinetic data also confirms the irreversible nature of the inhibition of TCPTP by EQ.

MOL # 116319

EQ alters TCPTP activity and enhance STAT1 phosphorylation in HL60 and Jurkat cells

Taking into consideration the *in vitro* effects of EQ observed with recombinant TCPTP protein, HL60 and Jurkat cell lines were treated with EQ to study its effect on cellular TCPTP. After 30 min exposure, the cells were lysed and cellular TCPTP immunoprecipitated. The residual TCPTP activity was measured using the phospho-STAT1 peptide substrate dephosphorylation assay using UFLC detection (Duval et al., 2015) and immunoprecipitated-TCPTP protein content evaluated by western blot. Figure 6 shows that upon exposure to EQ, the cellular TCPTP activity is decreased to roughly 30% and 50% that of the control cells in HL60 and Jurkat cells respectively. These data are consistent with studies carried out on the inhibition of PTP1B (a tyrosine phosphatase-related to TCPTP) by naphthoquinones (Iwamoto et al., 2007). These results indicate that EQ inhibits TCPTP in a cellular environment, and we therefore investigated whether, under such conditions, TCPTP-dependent intracellular signalling could be altered. Incubation of HL60 cells with IFN- γ triggers STAT1 phosphorylation signalling. This signalling is sustained at a higher level (1.5-fold for 60 minutes) in cells exposed to EQ treatment as compared with untreated controls (Figure 7A). Similar results were also obtained with Jurkat cells, with more than two-fold phosphorylation after 1 hour (Figure 7B). To further show that EQ increases STAT1 signaling, we measured the expression of three genes (*APOL1*, *GBP1* and *IRF1*) known to be regulated by STAT1 (Hartman et al., 2005; Reardon and McKay, 2007). As shown in supplementary figure 3, qPCR analyzes indicated that the expression of *APOL1*, *GBP1*, and *IRF1* is increased in Jurkat cells exposed to EQ. These results indicate that inhibition of TCPTP by EQ is associated with increased STAT1 phosphorylation and higher expression of STAT1-regulated genes in these cells upon stimulation with IFN- γ .

MOL # 116319

DISCUSSION

Etoposide is currently one of the most commonly used antitumor drugs. However, its use in clinics is associated with an increased risk of secondary leukaemia (Pendleton et al., 2014). Several threads of experimental evidence indicate that EQ, a reactive metabolite of ETOP, is involved in ETOP-related leukaemia through alteration of topoisomerase II function (Gantchev et al., 1997; Kagan et al., 1999; Fan et al., 2006; Vlasova et al., 2011; Jacob et al., 2011; Smith et al., 2014; Gibson et al., 2016;). However, effects of EQ on other cellular targets could also contribute to ETOP-related leukaemogenesis (Haim et al., 1987; Fan et al., 2006; Rojas et al., 2009). We investigated the possibility of protein tyrosine phosphatase TCPTP being a target of EQ. TCPTP plays a pivotal role in normal and malignant haematopoiesis through the negative regulation of the JAK/STAT signalling pathway (Dorritie et al., 2014). Interestingly, ETOP was reported to activate STAT1 signalling in HeLa cells. In addition, it has been shown that protein tyrosine phosphatases similar to TCPTP could be inhibited by polyaromatic quinones (Wang et al., 2004; Iwamoto et al., 2007). In line with this, we found in this work that EQ, the quinone metabolite of ETOP, was able to inhibit cellular TCPTP activity with subsequent increase in tyrosine phosphorylation of STAT1 in hematopoietic cell lines. Using further molecular and kinetic approaches, we show that EQ is an irreversible inhibitor of TCPTP. The second-order rate constant (k_{inact}) for this inhibition was found to be $\sim 810 \text{ M}^{-1} \cdot \text{min}^{-1}$ (Figure 5B). This rate constant is close to values found for naphthoquinone-dependent inhibition of human protein-tyrosine phosphatase 1B ($420 \text{ M}^{-1} \cdot \text{min}^{-1}$), a tyrosine phosphatase structurally-related to TCPTP (Wang et al., 2004). Interestingly, naphthoquinones have been shown to alter cell signalling, in particular through increased tyrosine phosphorylation (Iwamoto et al., 2007; Klotz and Jacob, 2014). In addition, the k_{inact} value for the inhibition of TCPTP by EQ is comparable to that reported

MOL # 116319

previously for hydrogen peroxide ($600 \text{ M}^{-1} \cdot \text{min}^{-1}$), a known endogenous regulator of tyrosine protein phosphatases (Seiner et al., 2007; Ostman et al., 2011). Inhibition of TCPTP by EQ was not reversed by buffer-exchange (Figure 4A). This observation, along with the time-dependent nature of the reaction (Figure 5A) indicates that the inhibition of TCPTP by EQ is irreversible. The activity of protein-tyrosine phosphatases such as TCPTP is well known to rely on a reactive active site cysteine that can be modified by oxidants or electrophilic chemicals with subsequent loss of activity and altered cell signalling (Ostman et al., 2011; Klotz et al., 2014). In addition, several quinones, such as EQ, are Michael acceptors that can covalently react with cysteine residues to form irreversible adducts (Giorgianni et al., 2006; Fan et al., 2006; Bolton et al., 2018). Accordingly, we found that the irreversible nature of the inhibition of TCPTP by EQ is due to formation covalent adducts on the catalytic cysteine residue of the enzyme (Cysteine 216). This was confirmed by the fact that the inhibition process of TCPTP by EQ was slowed by addition of the competitive TCPTP inhibitor orthovanadate and by computational docking approaches. More importantly, mass spectrometry analysis of TCPTP inhibited by EQ shows that the active site cysteine residue of the enzyme is indeed adducted by EQ (Figure 3C). Interestingly, recent experimental data indicate that EQ poisons topoisomerases II enzymes through cysteine adduction mechanisms and that this covalent modification of topoisomerases II by EQ is likely to contribute to ETOP-related leukaemogenesis (Jacob et al., 2011; Smith et al., 2014). Of note, the activity of EQ against topoisomerase II α was found to be considerably higher than that of ETOP. Indeed, EQ can inhibit DNA relaxation at 100-fold lower levels ($1 \text{ }\mu\text{M}$ versus $100 \text{ }\mu\text{M}$) of drug when compared to ETOP (Gibson et al., 2016). In their study on the inhibition of topoisomerase II β by EQ and ETOP, Smith *et al.* reported that while $15 \text{ }\mu\text{M}$ EQ inhibited DNA cleavage by Topo2 β in 6 min less than 15% inhibition was observed with the parent drug

MOL # 116319

ETOP (Smith et al., 2014). In addition, EQ is able to inhibit ATP hydrolysis by topoisomerase II α whereas ETOP cannot (Gibson et al., 2016). Interestingly, while EQ was found to inhibit TCPTP, the parent drug did not. This is in agreement with the electrophilic nature of EQ which enables it to covalently react with the catalytic cysteine of TCPTP through Michael addition (Fan et al., 2006; Bolton et al., 2018). Tyrosine phosphatases closely related to TCPTP such as PTP1B have been shown to be inhibited by naphthoquinones through active site cysteine covalent modification (Iwamoto et al., 2007; Klotz et al., 2014). We found that EQ was also able to inhibit the phosphatase activity of PTP1B (supplementary figure 4). Although we cannot rule out that EQ may affect STAT1 tyrosine phosphorylation through effects on other tyrosine phosphatases, siRNA-mediated knockout of TCPTP in Jurkat cells and knockout mice models clearly indicate that impairment of TCPTP activity strongly impacts STAT1 tyrosine phosphorylation (Simoncic et al., 2002; Kleppe et al., 2010). Increasing evidence indicates that CYP/myeloperoxidase-dependent oxidative activation of ETOP into reactive metabolites (notably EQ) in hematopoietic cells is a key contributor to ETOP-related leukaemia (Zhuo et al., 2004; Fan et al., 2006; Jacob et al., 2011; Vlasova et al., 2011; Smith et al., 2014; Gibson et al., 2016; Atwal et al., 2017). We show here that in addition to disruption of topoisomerases II functions, EQ could also contribute to ETOP-related leukaemia through interactions with TCPTP and subsequent cell signalling alteration.

ACKNOWLEDGEMENTS

We thank the technical platform “BioProfiler-UFLC” (BFA Unit, Paris Diderot University) for provision of UFLC facilities. We are grateful to Dr. Oliver Brookes for English language proofreading of this manuscript.

MOL # 116319

AUTHORS CONTRIBUTION

Participated in research design: QN, JB, FRL

Conducted experiments: QN, JB, L-CB, SG, TL

Performed data analysis: QN, JB, WZ, L-CB, RL, RD, SG, TL, CC, FG, FB, J-MD, FRL

Wrote or contributed to the writing of the manuscript: QN, JB, XX, SG, TL, FB, FRL

MOL # 116319

REFERENCES

- Atwal M, Lishman EL, Austin CA, Cowell IG (2017). Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy. *Mol Pharmacol* 91: 49-57.
- Baldwin EL, Osheroff N (2005). Etoposide, topoisomerase II and cancer. *Curr Med Chem Anticancer Agents* 5: 363-372.
- Benekli M, Baumann H, Wetzler M (2009). Targeting signal transducer and activator of transcription signaling pathway in leukemias. *J Clin Oncol* 27: 4422-4432.
- Bolton JL, Dunlap T (2017). Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects. *Chem Res Toxicol* 30: 13-37.
- Bolton JL, Dunlap TL, Dietz BM (2018). Formation and biological targets of botanical o-quinones. *Food Chem Toxicol* 120: 700-707.
- Bourdeau A, Dube N, Heinonen KM, Theberge JF, Doody KM, Tremblay ML (2007). TCPTP-deficient bone marrow stromal cells fail to support normal B lymphopoiesis due to abnormal secretion of interferon- γ . *Blood* 109: 4220-4228.
- Deweese JE, Osheroff N (2009). Coordinating the two protomer active sites of human topoisomerase II α : nicks as topoisomerase II poisons. *Biochemistry* 48: 1439-1441.
- Dorritie KA, McCubrey JA, Johnson DE (2014). STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. *Leukemia* 28: 248-257.
- Paz MA, Fluckiger R, Boak A, Kagan HM, Gallop PM (1991). Specific detection of quinoproteins by redox-cycling staining. *J Biol Chem* 266: 689-692.
- Duval R, Bui LC, Berthelet J, Dairou J, Mathieu C, Guidez F, *et al.* (2015). A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2). *Sci Rep* 5: 10750.
- Fan Y, Schreiber EM, Giorgianni A, Yalowich JC, Day BW (2006). Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. *Chem Res Toxicol* 19: 937-943.
- Gantchev TG, Hunting DJ (1998). The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. *Mol Pharmacol* 53: 422-428.
- Gibson EG, King MM, Mercer SL, Deweese JE (2016). Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase II α . *Chem Res Toxicol* 29: 1541-1548.

MOL # 116319

Haim N, Nemeč J, Roman J, Sinha BK (1987). Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. *Cancer Res* 47: 5835-5840.

Hande KR (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. *Eur J Cancer* 34: 1514-1521.

Hartman S E, Bertone P, Nath AK, Royce TE, Gerstein M, Weissman S, Snyder M. (2005). Global changes in STAT target selection and transcription regulation upon interferon treatments. *Genes Dev* 19: 2953-2968.

Heinonen KM, Bourdeau A, Doody KM, Tremblay ML (2009). Protein tyrosine phosphatases PTP-1B and TCPTP play nonredundant roles in macrophage development and IFN-gamma signaling. *Proc Natl Acad Sci U S A* 106: 9368-9372.

Humphrey W, Dalke A, Schulten K (1996). VMD: visual molecular dynamics. *J Mol Graph* 14: 33-38, 27-38.

Iwamoto N, Sumi D, Ishii T, Uchida K, Cho AK, Froines JR, *et al.* (2007). Chemical knockdown of protein-tyrosine phosphatase 1B by 1,2-naphthoquinone through covalent modification causes persistent transactivation of epidermal growth factor receptor. *J Biol Chem* 282: 33396-33404.

Jacob DA, Mercer SL, Osheroff N, Dewese JE (2011). Etoposide quinone is a redox-dependent topoisomerase II poison. *Biochemistry* 50: 5660-5667.

Kagan VE, Yalowich JC, Borisenko GG, Tyurina YY, Tyurin VA, Thampatty P, *et al.* (1999). Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. *Mol Pharmacol* 56: 494-506.

Kleppe M, Lahortiga I, El Char T, De Keersmaecker K, Mentens N, Graux C, *et al.* (2010). Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. *Nat Genet* 42: 530-535.

Kleppe M, Soulier J, Asnafi V, Mentens N, Hornakova T, Knoops L, *et al.* (2011a). PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. *Blood* 117: 7090-7098.

Kleppe M, Tousseyn T, Geissinger E, Kalender Atak Z, Aerts S, Rosenwald A, *et al.* (2011b). Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma. *Haematologica* 96: 1723-1727.

Klotz LO, Hou X, Jacob C (2014). 1,4-naphthoquinones: from oxidative damage to cellular and inter-cellular signaling. *Molecules* 19: 14902-14918.

MOL # 116319

Li Y, Jongberg S, Andersen ML, Davies MJ, Lund MN (2016). Quinone-induced protein modifications: Kinetic preference for reaction of 1,2-benzoquinones with thiol groups in proteins. *Free Radic Biol Med* 97: 148-157.

Montalibet J, Skorey KI, Kennedy BP (2005). Protein tyrosine phosphatase: enzymatic assays. *Methods* 35: 2-8.

Ostman A, Frijhoff J, Sandin A, Bohmer FD (2011). Regulation of protein tyrosine phosphatases by reversible oxidation. *J Biochem* 150: 345-356.

Pendleton M, Lindsey RH, Jr., Felix CA, Grimwade D, Osheroff N (2014). Topoisomerase II and leukemia. *Ann N Y Acad Sci* 1310: 98-110.

Pike KA, Tremblay ML (2016). TCPTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. *Cytokine* 82: 52-57.

Reardon C, McKay D M (2007). TGF-beta suppresses IFN-gamma-STAT1-dependent gene transcription by enhancing STAT1-PIAS1 interactions in epithelia but not monocytes/macrophages. *J Immunol* 178: 4284-4295.

Rojas E, Mussali P, Tovar E, Valverde M (2009). DNA-AP sites generation by etoposide in whole blood cells. *BMC Cancer* 9: 398.

Seiner DR, LaButti JN, Gates KS (2007). Kinetics and mechanism of protein tyrosine phosphatase 1B inactivation by acrolein. *Chem Res Toxicol* 20: 1315-1320.

Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ (2002). The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. *Curr Biol* 12: 446-453.

Smith NA, Byl JA, Mercer SL, Dewese JE, Osheroff N (2014). Etoposide quinone is a covalent poison of human topoisomerase IIbeta. *Biochemistry* 53: 3229-3236.

Schneider CA, Rasband WS, Eliceiri KW (2012). NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 9:671-675.

ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, *et al.* (2002). Identification of a nuclear Stat1 protein tyrosine phosphatase. *Mol Cell Biol* 22: 5662-5668.

Tiganis T, Bennett AM (2007). Protein tyrosine phosphatase function: the substrate perspective. *Biochem J* 402: 1-15.

Tonks NK (2006). Protein tyrosine phosphatases: from genes, to function, to disease. *Nat Rev Mol Cell Biol* 7: 833-846.

MOL # 116319

Vlasova, II, Feng WH, Goff JP, Giorgianni A, Do D, Gollin SM, *et al.* (2011). Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells. *Mol Pharmacol* 79: 479-487.

Wang Q, Dube D, Friesen RW, LeRiche TG, Bateman KP, Trimble L, *et al.* (2004). Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones. *Biochemistry* 43: 4294-4303.

Wiede F, Chew SH, van Vliet C, Poulton IJ, Kyparissoudis K, Sasmono T, *et al.* (2012). Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in *ptpn2*-deficient mice. *PLoS One* 7: e36703.

Young RM, Polsky A, Refaeli, Y. (2009). TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas. *Blood* 114: 5016-5023

You-Ten KE, Muise ES, Itie A, Michalyszyn E, Wagner J, Jothy S, *et al.* (1997). Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. *J Exp Med* 186: 683-693.

Zhuo X, Zheng N, Felix CA, Blair IA (2004). Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. *Drug Metab Dispos* 32: 993-1000.

MOL # 116319

FOOTNOTES

This work was supported by University Paris Diderot and CNRS. QN, WZ and RL are supported by China Scholarship Council (CSC) PhD fellowships. JB was supported by a PhD fellowship from Région Ile de France (Cancéropole 2015).

MOL # 116319

LEGEND FIGURES

Figure 1: Effect of ETOP and EQ on human TCPTP activity

(A) Effect of ETOP and EQ on TCPTP activity measured by pNPP dephosphorylation. 1 μ M TCPTP was incubated with 100 μ M ETOP and 5 to 40 μ M EQ for 30 min at 37°C and diluted 10-fold prior to measurement of residual activity in the presence of 5 mM pNPP as described in the Methods section. Results are the mean of three independent experiments, error bars indicate S.D.

(B) Measurements of TCPTP FAM-pSTAT1 peptide dephosphorylation activity. TCPTP was incubated with 100 μ M ETOP and 40 μ M EQ for 30 min at 37°C and residual PTPN2 activity measured as described under Methods. Results are the mean of three independent experiments, error bars indicate S.D. * $p < 0.05$ determined using ANOVA followed by Dunnett's post-hoc analysis.

Figure 2: Modification of TCPTP cysteine residues by EQ

(A) Detection of Human TCPTP adducts by NBT staining. Human TCPTP was incubated with 40 μ M EQ or 100 μ M ETOP for 30 min. Samples were separated by SDS-PAGE and transferred onto nitrocellulose membrane. Quinone adducts were detected by NBT staining as described in Methods. Membrane is representative of 3 independent experiments.

(B) 5-IAF staining of Human TCPTP to detect unmodified cysteines. Human TCPTP was incubated with 40 μ M EQ or 100 μ M ETOP for 30 min prior incubation for 10 min with 20 μ M 5-IAF. SDS-PAGE and transferred onto nitrocellulose membrane. IAF adducts were detected by fluorescence after SDS-PAGE as described in Methods section. Membrane is representative of 3 independent experiments.

(C) Detection of TCPTP protein oxidation. Human TCPTP was incubated with 100 μ M ETOP, 40 μ M EQ or 100 μ M H₂O₂ for 30 min prior analysis with western blot using an anti-oxidized TCPTP active site antibody as described in Methods. Membrane is representative of 3 independent experiments.

Figure 3: Mapping of EQ adduct on TCPTP protein active site cysteine

(A) Effect of sodium orthovanadate on TCPTP inhibition by EQ. 1 μ M Human recombinant TCPTP was incubated with 40 μ M EQ and/or 1 mM orthovanadate for 30 min at 37°C and residual activity measured as described in Methods. Experiment is representative of 3 independent experiments.

(B) Molecular docking model of EQ bound in human TCPTP protein structure. EQ molecule adduct atom coordinates were obtained inside TCPTP active site pocket as described in the Methods section. EQ is displayed with green sticks and is covalently bonded to the C216 residue.

(C) Mass spectrometry characterization of EQ adduct on the active site cysteine tryptic peptide. 1 μ M TCPTP protein was incubated with 100 μ M EQ for 30 min at 37°C prior trypsin treatment and LC-MS/MS analysis as described in Methods. Upper panel depicts the spectrum obtained with control untreated TCPTP protein whereas lower panel shows data acquired with TCPTP samples treated with EQ. The sequence of the peptide is displayed on each panel in addition to the position of the EQ adduct on cysteine in lower panel.

MOL # 116319

Figure 4: Irreversibility of TCPTP inhibition by EQ

(A) Effect of buffer exchange on activity of TCPTP preincubated with EQ. Human TCPTP was incubated with 40 μM EQ or 100 μM ETOP for 30 min followed by buffer exchange or not prior to residual pNPP dephosphorylation activity determination as described in Methods. Results are the mean of three independent experiments, error bars indicate S.D. * $p < 0.05$ determined using ANOVA followed by Dunnett's post-hoc analysis.

(B) Effect of DTT on activity of TCPTP preincubated with EQ. Human TCPTP was preincubated or not with 40 μM EQ for 30 min followed by the treatment with 1 or 10 mM DTT. Residual pNPP dephosphorylation activity was determined as described in Methods. Results are the mean of three independent experiments, error bars indicate S.D. * $p < 0.05$ determined using ANOVA followed by Dunnett's post-hoc analysis.

Figure 5: Kinetics of TCPTP inhibition by EQ

(A) Determination of pseudo-first order inhibition rate constant for TCPTP inhibition by EQ. 3 μM TCPTP was incubated with different concentrations (0, 10, 20 and 40 μM) of EQ and assayed for residual activity at different time points as described in Methods. k_{obs} was determined as the slope of the linear regression of data expressed as the natural logarithm of the residual activity as a function of time. Results are the mean of three independent experiments, error bars indicate S.D.

(B) Determination of the second order inhibition rate constant for TCPTP inhibition by EQ. k_{obs} were plotted as a function of EQ concentration and the k_{inact} was determined as the slope of the linear regression as described in Methods. Results are the mean of three independent experiments, error bars indicate S.D.

Figure 6: Inhibition of TCPTP by EQ in HL60 and Jurkat cells

HL60 (A) and Jurkat cells (B) were treated or not (Ctrl) with 50 μM EQ for 30 min at 37°C. Cells were lysed and cellular TCPTP protein was immunoprecipitated prior to residual activity determination and TCPTP protein content determination by western blotting as described in Methods. Results are the mean of three independent experiments, error bars indicate S.D. * $p < 0.05$ determined using Student's t test as described under Methods section. Western blot is representative of 3 independent experiments.

Figure 7: STAT1 phosphorylation kinetic analysis in HL60 and Jurkat cells induced with IFN γ

HL60 (A) and Jurkat cells (B) were treated or not (Ctrl) with 50 μM EQ for 30 min at 37°C, then washed prior to incubation for 20 min with IFN γ . Washed cells were then analyzed at different time points as described in Methods. Results are the mean of three independent experiments, error bars indicate S.D. * $p < 0.05$ determined using Student's t test as described under Methods section. Western blot is representative of 3 independent experiments. Quantification of STAT1 phosphorylation in western blots was carried out using ImageJ software.





Figure 1




Figure 2






Figure 3






Figure 4

A



B




Figure 5




Figure 6




Figure 7